1. Scrip
  2. >>Therapy Areas

BMS Moves Closer To Subcutaneous Opdivo With Phase III Trial Success

 
• By Joseph Haas

A Phase III trial testing subcutaneous nivolumab versus the intravenous product hits pharmacokinetic and efficacy endpoints. BMS, Roche and Merck & Co. all are seeking subcutaneous versions of their anti-PD-1/L1 blockbusters.

Chemical process
Bristol makes progress in formulating a subcutaneous version of Opdivo • Source: Shutterstock

Bristol Myers Squibb Company unveiled top-line Phase III data on 19 October that should aid its effort to obtain regulatory approval of a subcutaneous formulation of its blockbuster PD-1 inhibitor Opdivo (nivolumab), which currently is administered as an intravenous therapy in numerous cancer indications. The company has previously said successful data in one cancer setting would be sufficient for approval of the subcutaneous formulation in all monotherapy settings for which Opdivo is indicated.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer